EL7.AI
StocksMediumUpdated×3•Originally published 30 August 2026•Updated 31 August 2026•
1 min read

Arrowhead Reports Positive Phase 3 Data for Plozasiran in Hypertriglyceridemia

Vial of Plozasiran by Arrowhead Pharmaceuticals with a shielded pancreas and exploding cells on an orange background.

Key Facts

1Phase 3 SHASTA-3 and SHASTA-4 data demonstrated that plozasiran reduced acute pancreatitis events in patients with severe hypertriglyceridemia.

In a move reflecting the ongoing innovation within the biotech sector, Arrowhead Pharmaceuticals has announced pivotal Phase 3 clinical trial results. According to reports, data from the SHASTA-3 and SHASTA-4 studies demonstrated that the drug plozasiran significantly reduced acute pancreatitis events in adults with severe hypertriglyceridemia. This successful late-stage milestone is critical for the drug's regulatory approval path and eventual commercialization.

This development comes as biotechnology firms prioritize de-risking their primary pipeline candidates to secure market confidence. The company intends to leverage this data to seek marketing authorization across multiple global jurisdictions.

Looking ahead, Arrowhead is scheduled to host a conference call to discuss the detailed results on August 31, 2026.

Open on chart